CENCORA Aktie

 

Battaglia, Silvana - Vorstand - Tag der Transaktion: 2025-12-19...

Campbell, Elizabeth S. - Vorstand - Tag der Transaktion: 2025-12-19...

Mauch, Robert P. - Vorstand - Tag der Transaktion: 2025-12-18...

IRVINE, Calif.--(BUSINESS WIRE)--RIS Rx, a healthcare technology company offering gross-to-net (GTN) revenue protection and saving more than $1 billion for the world's leading pharmaceutical manufacturers, today announced the appointment of Leslie Donato to its Board of Directors. Ms. Donato is a highly accomplished healthcare executive with more than 30 years of experience in corporate strategy, commercialization, and enterprise growth. Most recently, she served as Executive Vice President and Chief Strategy Officer at Cencora, where she played a vital role in shaping the company's strategic direction, leading transformative M&A activity and contributing to a 130% increase in the company's market capitalization over five years. Prior to Cencora, Ms. Donato held leadership positions at Bayer Healthcare Pharmaceuticals and spent 14 years as a Principal in McKinsey & Company's Pharmaceutical & Medical Products Practice. She serves on the boards of multiple healthcare and life sciences organizations incl...

Krikorian, Lazarus - Vorstand - Tag der Transaktion: 2025-12-17...

COR's $3.6 billion move to take control of OneOncology boosts its pharma-centric strategy and lifts its long-term growth outlook despite a short-term dip....

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

Cencora agrees to buy a majority stake in OneOncology for about $5 billion, pauses buybacks, and reiterates fiscal 2026 sales and EPS guidance. read more...

WASHINGTON (dpa-AFX) - Cencora, Inc. (COR) on Monday said it has agreed to acquire the majority of the outstanding equity interests it does not already own in OneOncology, a physician-led platform......

NASHVILLE, Tenn., Dec. 15, 2025 /PRNewswire/ -- Cencora, Inc. today announced it has entered into a definitive agreement to acquire TPG's equity interest in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology. The......

Company reiterates fiscal 2026 guidance Company raises long-term guidance expectations to reflect OneOncology's expected long-term contribution to enterprise growth CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, from TPG, a leading global alternative asset management firm. “We are excited to accelerate our acquisition of OneOncology, which will advance our management services organization and aligns with our approach of making growth-oriented investments that support our pharmaceutical-centric strategy,” said Bob Mauch, President & CEO of Cencora. “Since our initial investment in OneOncology, the platform has grown substantially as its physician-led approach continues to attract leading practices and physicians, suppo...

Here is how Cencora (COR) and CorMedix (CRMD) have performed compared to their sector so far this year....

read more...

Cencora (COR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues....

Mauch, Robert P. - Vorstand - Tag der Transaktion: 2025-11-18...

KULTURA BRANDS (OTCID: LTNC) ANNOUNCES OFFICIAL LAUNCH ELEVATE HEALTH & WELLNESS GUMMIES NOW AVAILABLE FOR B2B THROUGH CENCORA MARKETPLACE AND DIRECT-TO-CONSUMER AT LOCKDIN.COM; THIRST RESPONDER HY......

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....